Slingshot members are tracking this event:
FDA Accepts NDA for Amgen's (AMGN) Etelcalcetide in Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis
Slingshot Insights Explained
Nov 06, 2015
Don’t see a project related to the catalyst you care about?
Related Keywords Etelcalcetide, Secondary Hyperparathyroidism, Chronic Kidney Disease, Hemodialysis, Calcimimetic Agent